Quantitative Profiles of the MRNAs of ER-alpha and Its Novel Variant ER-alpha36 in Breast Cancers and Matched Normal Tissues

Overview

Journal J Zhejiang Univ Sci B

Specialties Biology
General Medicine

Date 2010 Jan 28

PMID 20104649

Citations 8

Authors

Yi Zheng

Jing Zhang

Zhen-Zhen Xu

Jian-Ming Sheng

Xiao-Chen Zhang

Hao-Hao Wang

Xiao-Dong Teng

Xiao-Jiao Liu

Jiang Cao

Li-Song Teng

Affiliations

Soon will be listed here.

Abstract

Objective: The novel estrogen receptor-alpha (ER-alpha) variant ER-alpha36 is reported to be functional in the estrogen signaling pathway and is related to tamoxifen resistance in breast cancer. However, ER-alpha36 tends to be a favorable factor for survival in patients without tamoxifen therapy. To investigate the mechanisms behind this paradox, we determined the differences between the transcriptional profiles of ER-alpha36 and full-length ER-alpha (ER-alpha66) in breast cancers and matched normal tissues.

Methods: We analyzed ER-alpha36 and ER-alpha66 messenger RNA (mRNA) levels in 74 pairs of breast cancers and matched normal tissues using a real-time quantitative polymerase chain reaction (PCR) assay, and correlated the results with their clinicopathological characteristics.

Results: Breast cancers expressed lower ER-alpha36 mRNA levels than matched normal tissues regardless of their ER-alpha66 expression status. Down-regulation of ER-alpha36 mRNA was correlated with local progression, lymph node metastasis, and advanced cancer stage. The level of ER-alpha66 mRNA was lower in ER-alpha negative breast cancers compared with matched normal tissues. No differences in ER-alpha66 mRNA levels were observed during cancer progression.

Conclusion: Down-regulation of ER-alpha36 is associated with carcinogenesis and progression of breast cancer.

Citing Articles

ERα36-GPER1 Collaboration Inhibits TLR4/NFκB-Induced Pro-Inflammatory Activity in Breast Cancer Cells.

Notas G, Panagiotopoulos A, Vamvoukaki R, Kalyvianaki K, Kiagiadaki F, Deli A Int J Mol Sci. 2021; 22(14).

PMID: 34299224 PMC: 8303269. DOI: 10.3390/ijms22147603.

The Role of ERα36 in Development and Tumor Malignancy.

Thiebaut C, Konan H, Guerquin M, Chesnel A, Livera G, Le Romancer M Int J Mol Sci. 2020; 21(11).

PMID: 32526980 PMC: 7312586. DOI: 10.3390/ijms21114116.

Expression patterns of ERα66 and its novel variant isoform ERα36 in lactotroph pituitary adenomas and associations with clinicopathological characteristics.

Mahboobifard F, Bidari-Zerehpoosh F, Davoudi Z, Panahi M, Dargahi L, Pourgholami M Pituitary. 2020; 23(3):232-245.

PMID: 32026205 DOI: 10.1007/s11102-020-01029-z.

Estrogen receptor variant ER-α36 promotes tamoxifen agonist activity in glioblastoma cells.

Qu C, Ma J, Zhang Y, Han C, Huang L, Shen L Cancer Sci. 2018; 110(1):221-234.

PMID: 30417588 PMC: 6317923. DOI: 10.1111/cas.13868.

Protein arginine N-methyltransferase 2 reverses tamoxifen resistance in breast cancer cells through suppression of ER-α36.

Shen Y, Zhong J, Liu J, Liu K, Zhao J, Xu T Oncol Rep. 2018; 39(6):2604-2612.

PMID: 29620287 PMC: 5983932. DOI: 10.3892/or.2018.6350.

References

Gotteland M, Desauty G, DELARUE J, Liu L, May E . Human estrogen receptor messenger RNA variants in both normal and tumor breast tissues. Mol Cell Endocrinol. 1995; 112(1):1-13. DOI: 10.1016/0303-7207(95)03576-s. View

Kumar V, Green S, Stack G, Berry M, Jin J, Chambon P . Functional domains of the human estrogen receptor. Cell. 1987; 51(6):941-51. DOI: 10.1016/0092-8674(87)90581-2. View

Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun M . Cancer statistics, 2009. CA Cancer J Clin. 2009; 59(4):225-49. DOI: 10.3322/caac.20006. View

Leygue E, Huang A, Murphy L, Watson P . Prevalence of estrogen receptor variant messenger RNAs in human breast cancer. Cancer Res. 1996; 56(19):4324-7. View

Kumar V, Kumar S, Srivastava A, Kumar V . Observations on the presence of E domain variants of estrogen receptor-alpha in the breast tumors. J Surg Oncol. 2006; 94(4):332-7. DOI: 10.1002/jso.20588. View

Livak K, Schmittgen T . Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2002; 25(4):402-8. DOI: 10.1006/meth.2001.1262. View

Pfeffer U, Fecarotta E, Vidali G . Coexpression of multiple estrogen receptor variant messenger RNAs in normal and neoplastic breast tissues and in MCF-7 cells. Cancer Res. 1995; 55(10):2158-65. View

Koduri S, Fuqua S, Poola I . Alterations in the estrogen receptor alpha mRNA in the breast tumors of African American women. J Cancer Res Clin Oncol. 2000; 126(5):291-7. DOI: 10.1007/s004320050345. View

Kong E, Pike A, Hubbard R . Structure and mechanism of the oestrogen receptor. Biochem Soc Trans. 2003; 31(Pt 1):56-9. DOI: 10.1042/bst0310056. View

10.

Dunnwald L, Rossing M, Li C . Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients. Breast Cancer Res. 2007; 9(1):R6. PMC: 1851385. DOI: 10.1186/bcr1639. View

11.

Poola I, Speirs V . Expression of alternatively spliced estrogen receptor alpha mRNAs is increased in breast cancer tissues. J Steroid Biochem Mol Biol. 2001; 78(5):459-69. DOI: 10.1016/s0960-0760(01)00118-2. View

12.

Anandappa S, Sibson R, Platt-Higgins A, Winstanley J, Rudland P, Barraclough R . Variant estrogen receptor alpha mRNAs in human breast cancer specimens. Int J Cancer. 2000; 88(2):209-16. DOI: 10.1002/1097-0215(20001015)88:2<209::aid-ijc10>3.0.co;2-m. View

13.

Goldhirsch A, Glick J, Gelber R, Coates A, Thurlimann B, Senn H . Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol. 2005; 16(10):1569-83. DOI: 10.1093/annonc/mdi326. View

14.

Strom A, Hartman J, Foster J, Kietz S, Wimalasena J, Gustafsson J . Estrogen receptor beta inhibits 17beta-estradiol-stimulated proliferation of the breast cancer cell line T47D. Proc Natl Acad Sci U S A. 2004; 101(6):1566-71. PMC: 341775. DOI: 10.1073/pnas.0308319100. View

15.

Garcia Pedrero J, Zuazua P, Martinez-Campa C, Lazo P, Ramos S . The naturally occurring variant of estrogen receptor (ER) ERDeltaE7 suppresses estrogen-dependent transcriptional activation by both wild-type ERalpha and ERbeta. Endocrinology. 2003; 144(7):2967-76. DOI: 10.1210/en.2002-0027. View

16.

Wang Z, Zhang X, Shen P, Loggie B, Chang Y, Deuel T . A variant of estrogen receptor-{alpha}, hER-{alpha}36: transduction of estrogen- and antiestrogen-dependent membrane-initiated mitogenic signaling. Proc Natl Acad Sci U S A. 2006; 103(24):9063-8. PMC: 1482566. DOI: 10.1073/pnas.0603339103. View

17.

Wang Z, Zhang X, Shen P, Loggie B, Chang Y, Deuel T . Identification, cloning, and expression of human estrogen receptor-alpha36, a novel variant of human estrogen receptor-alpha66. Biochem Biophys Res Commun. 2005; 336(4):1023-7. DOI: 10.1016/j.bbrc.2005.08.226. View

18.

Erenburg I, Schachter B, Mira y Lopez R, OSSOWSKI L . Loss of an estrogen receptor isoform (ER alpha delta 3) in breast cancer and the consequences of its reexpression: interference with estrogen-stimulated properties of malignant transformation. Mol Endocrinol. 1998; 11(13):2004-15. DOI: 10.1210/mend.11.13.0031. View

19.

Ponglikitmongkol M, Green S, Chambon P . Genomic organization of the human oestrogen receptor gene. EMBO J. 1988; 7(11):3385-8. PMC: 454836. DOI: 10.1002/j.1460-2075.1988.tb03211.x. View

20.

Lee L, Cao J, Deng H, Chen P, Gatalica Z, Wang Z . ER-alpha36, a novel variant of ER-alpha, is expressed in ER-positive and -negative human breast carcinomas. Anticancer Res. 2008; 28(1B):479-83. PMC: 2610490. View